Ownership and insider activity for Corcept Therapeutics Incorporated (CORT): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsychiatric disorders across the United States. Its primary commercial offering is Korlym (mifepristone) tablets, an oral medication taken once daily.
Price
| Price | $116.23 |
| Market Cap | $12.6B |
| Exchange | NASDAQ |
| Country | US |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $51.5M | $104.0M | $206.8M | $31.3M | $76.2M | $77.6M | $66.3M | $135.6M | $127.7M | $120.5M |
| Short-term Investments | 0 | 0 | 0 | $244.7M | $364.5M | $145.9M | $365.3M | $232.7M | $255.7M | $251.7M |
| Receivables | $9.9M | $28.2M | $17.6M | $19.9M | $26.2M | $29.0M | $46.9M | $56.8M | $58.1M | $59.8M |
| Inventory | $2.3M | $8.4M | $16.2M | $5.4M | $4.9M | $5.0M | $6.1M | $7.7M | $12.4M | $12.9M |
| Total Current Assets | $65.7M | $140.6M | $240.6M | $307.4M | $478.5M | $266.5M | $499.3M | $458.6M | $471.6M | $485.5M |
| Property, Plant & Equipment | $205,000 | $518,000 | $655,000 | $4.5M | $4.2M | $1.5M | $1.8M | $315,000 | $8.0M | $6.5M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $68.8M | $220.5M | $311.7M | $412.3M | $571.7M | $423.8M | $583.4M | $621.5M | $840.6M | $836.7M |
| Accounts Payable | $2.3M | $8.6M | $8.3M | $7.5M | $10.6M | $6.9M | $12.0M | $17.4M | $15.4M | $40.4M |
| Short-term Debt | $14.7M | 0 | 0 | $1.6M | $2.0M | $526,000 | $1.1M | $151,000 | $829,000 | 0 |
| Total Current Liabilities | $27.4M | $29.6M | $35.8M | $38.8M | $47.5M | $47.5M | $72.5M | $104.5M | $140.8M | $166.1M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $5.0M |
| Total Liabilities | $27.4M | $29.6M | $35.8M | $41.1M | $48.4M | $48.0M | $81.6M | $114.8M | $161.0M | $188.8M |
| Retained Earnings | -$322.3M | -$193.1M | -$117.7M | -$23.6M | $82.5M | $195.0M | $296.4M | $402.5M | $543.7M | $643.4M |
| Total Equity | $41.4M | $191.0M | $275.9M | $371.2M | $523.3M | $375.8M | $501.8M | $506.7M | $679.6M | $647.8M |
| Total Debt | $14.7M | 0 | 0 | $3.5M | $2.6M | $526,000 | $1.1M | $151,000 | $6.9M | $6.1M |
| Net Debt | -$36.9M | -$104.0M | -$206.8M | -$272.5M | -$438.1M | -$223.0M | -$430.5M | -$368.1M | -$376.4M | -$366.0M |
| Working Capital | $38.3M | $111.0M | $204.8M | $268.5M | $431.0M | $218.9M | $426.8M | $354.1M | $330.8M | $319.4M |
Financial Health
| Debt / Equity | 0.01 |
| Current Ratio | 2.86 |
| Piotroski F-Score | 4 |
| Altman Z-Score | 14.11 |
Profitability
| Return on Equity | 8.37% |
| Return on Invested Capital | 0.87% |
| Return on Assets | 6.18% |
| Gross Margin | 98.30% |
| Operating Margin | 0.77% |
| Net Margin | 6.61% |
Related companies: ABVX · AXSM · CAI · CYTK · HALO · JAZZ · MRUS
Explore sector: Healthcare · Medical - Pharmaceuticals
More sections of CORT: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks